Monday, October 23, 2023 8:57:49 AM
TC BioPharm (PRNewsfoto/TC BioPharm)
The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.
"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm. "The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team. I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."
The FDA will review the application and determine the acceptability of the data before TC BioPharm begins its first clinical trial for TCB-008 It is possible that the FDA will require additional information.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful”
Warren Buffett
Recent TCBP News
- TCBP Announces Launch of Compassionate Use Program for TCB008 • PR Newswire (US) • 05/15/2024 12:30:00 PM
- TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds • PR Newswire (US) • 05/06/2024 05:01:00 PM
- TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies • PR Newswire (US) • 05/06/2024 12:30:00 PM
- TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies • PR Newswire (US) • 04/04/2024 12:32:00 PM
- TCBP Increasing Treatment Capacity with Expanded Manufacturing Process • PR Newswire (US) • 04/02/2024 12:30:00 PM
- TCBP Adjourns General Meeting Until a Later Date • PR Newswire (US) • 03/19/2024 12:30:00 PM
- TCBP Announces Exercise of Series D Warrants For Cash • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:30:38 AM
- Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show" • PR Newswire (US) • 03/01/2024 01:30:00 PM
- /C O R R E C T I O N -- TC BioPharm/ • PR Newswire (US) • 02/27/2024 10:15:00 PM
- TCBP Announces Shareholder Update Call on March 5th 2024 • PR Newswire (US) • 02/27/2024 01:30:00 PM
- TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial • PR Newswire (US) • 02/22/2024 02:32:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/20/2024 11:05:14 AM
- TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe • PR Newswire (US) • 02/15/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 07:48:40 PM
- TCBP Provides Shareholder Update and Highlights Upcoming Milestones • PR Newswire (US) • 02/14/2024 01:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/09/2024 08:26:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 02:16:48 PM
- TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' • PR Newswire (US) • 01/29/2024 01:30:00 PM
- TC BioPharm to Present at the Sequire Investor Summit • PR Newswire (US) • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:46:05 PM
- TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 01/04/2024 01:30:00 PM
- TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies • PR Newswire (US) • 01/03/2024 01:30:00 PM
- TC BioPharm Announces Closing of $3.5 Million Public Offering • PR Newswire (US) • 12/22/2023 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 10:14:09 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM